REG - Oxford Biomedica PLC - PDMR Dealings

Oxford BioMedicaAnnouncement

26/09/2023 16:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230926:nRSZ7254Na&default-theme=true

RNS Number : 7254N  Oxford Biomedica PLC  26 September 2023

 

 

PDMR Dealings

 

Oxford, UK - 26 September 2023: Oxford Biomedica plc ("Oxford Biomedica" or
" the Company") (LSE:OXB), a quality and innovation-led viral vector CDMO,
today announces that Leone Patterson, Non-Executive Director, and Professor
Dame Kay Davies, Senior Independent Director, have both purchased ordinary
shares in the Company.

 

The ordinary shares purchased by Leone Patterson were acquired pursuant to the
Oxford Biomedica 2021 Remuneration Policy which was approved at the 2021
Annual General Meeting, where an additional fee of up to £50,000 per annum
may be paid to any Non-Executive Director recruited from or based in the
United States to reflect market levels of remuneration in the United States
for Non-Executive Directors, subject to their agreement that the after tax
amount of this additional fee will be used to acquire Oxford Biomedica shares
at market value, which must be retained for at least 12 months from
acquisition.

 

The following table sets out the number of shares purchased for each Director
and additional information.

 

 Name of PDMR     Number of ordinary shares purchased  Number of ordinary shares now held  Total number of ordinary shares held as a percentage of the Company's share
                                                                                           capital
 Leone Patterson  6,598                                12,447                              0.013%
 Kay Davies       1,000                                1,000                               0.001%

 

The below notifications, made in accordance with the requirements of the EU
Market Abuse Regulation, give further details of the number of ordinary shares
purchased.

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")
 a)  Name                                     Leone Patterson
 2.  Reason for the notification
 a)  Position/status                          Non-Executive Director

 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Oxford Biomedica plc
 b)  LEI code                                 213800S1GVQNXQ15K851
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 50 pence each

     Identification code

                                              ISIN: GB00BDFBVT43
 b)  Nature of the transaction                Purchase of shares
 c)  Currency                                 GBP - British pound
 d)  Price(s) and volumes(s)

Price(s)  Volume(s)
                                              £2.905    6,598

 e)  Aggregated information

     -    Aggregate volume                    6,598

     -    Aggregated total

                                              £19,167.19
 f)  Date of the transaction                  2023-09-26; 13:30
 g)  Place of the transaction                 London Stock Exchange, Main Market (XLON)

e)

Aggregated information

-    Aggregate volume

-    Aggregated total

 

 

6,598

 

 

£19,167.19

f)

Date of the transaction

2023-09-26; 13:30

g)

Place of the transaction

London Stock Exchange, Main Market (XLON)

 

 1.  Details of the Person Discharging Managerial Responsibility ("PDMR")
 a)  Name                                     Kay Davies
 2.  Reason for the notification
 a)  Position/status                          Senior Independent Director

 b)  Initial notification/                    Initial Notification

     amendment
 3.  Details of the Issuer
 a)  Name                                     Oxford Biomedica plc
 b)  LEI code                                 213800S1GVQNXQ15K851
 4.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Ordinary Shares of 50 pence each

     Identification code

                                              ISIN: GB00BDFBVT43
 b)  Nature of the transaction                Purchase of shares
 c)  Currency                                 GBP - British pound
 d)  Price(s) and volumes(s)

Price(s)  Volume(s)
                                              £2.91     1,000

 e)  Aggregated information

     -    Aggregate volume                    1,000

     -    Aggregated total

                                              £2,910
 f)  Date of the transaction                  2023-09-26; 12:37
 g)  Place of the transaction                 London Stock Exchange, Main Market (XLON)

e)

Aggregated information

-    Aggregate volume

-    Aggregated total

 

 

1,000

 

£2,910

f)

Date of the transaction

2023-09-26; 12:37

g)

Place of the transaction

London Stock Exchange, Main Market (XLON)

 

 

 

 

 

-Ends-

 

 For further information, please contact:

 Oxford Biomedica plc:                     Tel: +44 (0)1865 783 000

 Natalie Walter, Company Secretary

 

 

About Oxford Biomedica

 

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene
therapy CDMO with a mission to enable its clients to deliver life changing
therapies to patients around the world.

 

One of the original pioneers in cell and gene therapy, the Company has more
than 25 years of experience in viral vectors; the driving force behind the
majority of gene therapies. The Company collaborates with some of the world's
most innovative pharmaceutical and biotechnology companies, providing viral
vector development and manufacturing expertise in lentivirus, adeno-associated
virus (AAV) and adenoviral vectors. Oxford Biomedica's world-class
capabilities span from early-stage development to commercialisation. These
capabilities are supported by robust quality-assurance systems, analytical
methods and depth of regulatory expertise.

 

Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It
has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at
www.oxb.com (https://www.oxb.com/) , www.oxbsolutions.com
(https://oxbsolutions.com/) , and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica/) and YouTube
(https://www.youtube.com/user/OxfordBioMedica) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHFLFSSAEIRFIV